Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials
- 4.7k Downloads
EMPAREG OUTCOME study showed a reduction in cardiovascular events in patients treated with the sodium-glucose transporter 2 inhibitor (SGLT2i) empagliflozin, as compared to placebo. Other drugs of the same class are currently been investigated for cardiovascular outcomes. In the meanwhile, a re-analysis of data collected in available studies can add relevant insight.
A MEDLINE search for SGLT-2 inhibitors (dapagliflozin, empagliflozin, canagliflozin, ipragliflozin, ertugliflozin, luseogliflozin) was performed, collecting all randomized trials up to November 16, 2015. All trials with a duration of treatment ≥12 weeks, enrolling patients with type 2 diabetes, comparing a SGLT2i with placebo or other comparators were included. The principal outcome was the effect of SGLT2i on all-cause and cardiovascular mortality. Secondary endpoints were myocardial infarction and stroke. Mantel–Haenszel odds ratio with 95 % confidence interval (MH-OR) was calculated.
A total of 71 trials were included (31,199 and 16,088 patients in SGLT2i and comparator groups). Treatment with SGLT2i was associated with a significant reduction in all-cause mortality (MH-OR 0.70 [0.59–0.83], p < 0.001), cardiovascular mortality (MH-OR 0.43 [0.36–0.53], p < 0.001), and myocardial infarction (MH-OR 0.77 [0.63–0.94], p < 0.01), but not stroke (MH-OR 1.09 [0.86–1.38], p = 0.50), with no apparent difference across molecules (after excluding cardiovascular outcome trials).
Available data suggest that the beneficial action observed with empagliflozin on all-cause and cardiovascular mortality in EMPAREG OUTCOME study is a class effect. The present meta-analysis showed a significantly reduction in myocardial infarction, with no increased risk of stroke.
KeywordsSGLT-2 inhibitors Cardiovascular events Mortality Meta-analysis
This research was performed independently of any funding, as part of the institutional activity of the investigators.
Matteo Monami designed the study, collected the data, performed the analysis, and wrote the manuscript. Ilaria Dicembrini collected the data and revised the manuscript. Edoardo Mannucci designed the study, collected the data, performed the analysis, and wrote the manuscript. All the authors approved the final version of this manuscript.
Compliance with ethical standards
Conflict of interest
Matteo Monami has received speaking fees from Bristol Myers Squibb, Eli-Lilly, Merck, Novonordisk, Merck, and Takeda; and research grants from Bristol Myers Squibb. Ilaria Dicembrini has no conflicts of interest. Edoardo Mannucci has received consultancy fees from Merck and Novartis; speaking fees from Astra Zeneca, Bristol Myers Squibb, Merck, and Novartis; and research grants from Merck, Novartis, and Takeda.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Human and animal rights
This article does not contain any studies with animals performed by any of the authors.
For this type of study formal consent is not required.
- 9.CANVAS—CANagliflozin cardioVascular Assessment Study. https://www.clinicaltrial.gov/ct2/show/NCT01032629?term=canvas&rank=1. Last accessed 25 Jan 2016
- 10.Multicenter trial to evaluate the effect of dapagliflozin on the incidence of cardiovascular events (DECLARE-TIMI58). https://www.clinicaltrial.gov/ct2/show/NCT01730534?term=declare+dapagliflozin&rank=1. Last accessed 25 Jan 2016
- 11.Cardiovascular outcomes following treatment with ertugliflozin in participants with type 2 diabetes mellitus and established vascular disease (MK-8835-004). https://www.clinicaltrial.gov/ct2/show/NCT01986881?term=ertugliflozin+cardiovascular&rank=1. Last accessed 25 Jan 2016
- 12.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/204042Orig1s000MedR.pdf. Last accessed 25 Jan 2016
- 14.http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42015029573. Last accessed 25 Jan 2016
- 15.www.fda.gov. Last accessed on 25 Jan 2016
- 16.www.ema.europa.eu. Last accessed on 25 Jan 2016
- 20.Solini A (2016) Role of SGLT-2 inhibitors in the treatment of type 2 diabetes mellitus. Acta Diabetol. (Epub ahead of print)Google Scholar
- 21.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002649/WC500156457.pdf. Last accessed on 25 Jan 2016
- 22.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002677/WC500168592.pdf. Last accessed 25 Jan 2016
- 23.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204629Orig1s000MedR.pdf. Last accessed 25 Jan 2016
- 24.http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002322/WC500136026.pdf. Last accessed 25 Jan 2016
- 25.http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/202293Orig1s000MedR.pdf. Last accessed 25 Jan 2016
- 31.Mahaffey KW, Roe MT, Dyke CK et al (2002) Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network Trial. Am Heart J 143:242–248CrossRefPubMedGoogle Scholar
- 38.Inagaki N, Kondo K, Yoshinari T, Takahashi N, Susuta Y, Kuki H (2014) Efficacy and safety of canagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled with diet and exercise: a 24-week, randomized, double-blind, placebo-controlled, Phase III study. Expert Opin Pharmacother 15:1501–1515CrossRefPubMedGoogle Scholar
- 44.Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K (1995) Efficacy and safety of canagliflozin treatment in older subjects with type 2 diabetes mellitus: a randomized trial. Hosp Pract 2013(41):72–84Google Scholar
- 46.Cefalu WT, Leiter LA, Yoon KH et al (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382:941–950CrossRefPubMedGoogle Scholar
- 48.Kaku K, Inoue S, Matsuoka O et al (2013) Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab 15:432–440CrossRefPubMedGoogle Scholar
- 52.Weber MA, Mansfield TA, Cain VA, Iqbal N, Parikh S, Ptaszynska A (2015) Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol. (Epub ahead of print)Google Scholar
- 57.Rosenstock J, Hansen L, Zee P et al (2015) Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38:376–383CrossRefPubMedGoogle Scholar
- 62.Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S (2011) Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 13:928–938CrossRefPubMedGoogle Scholar
- 63.Cefalu WT, Leiter LA, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ (2015) Dapagliflozin’s effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. Diabetes Care 38:1218–1227CrossRefPubMedPubMedCentralGoogle Scholar
- 65.Yang W, Han P, Min KW et al (2015) Efficacy and safety of dapagliflozin in Asian patients with type 2 diabetes after metformin failure: a randomized controlled trial. J Diabetes. (Epub ahead of print)Google Scholar
- 66.Rosenstock J, Vico M, Wei L, Salsali A, List JF (2012) Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 35:1473–1478CrossRefPubMedPubMedCentralGoogle Scholar
- 68.Leiter LA, Cefalu WT, de Bruin TW, Gause-Nilsson I, Sugg J, Parikh SJ (2014) Dapagliflozin added to usual care in individuals with type 2 diabetes mellitus with preexisting cardiovascular disease: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension. J Am Geriatr Soc 62:1252–1262CrossRefPubMedGoogle Scholar
- 75.Ferrannini E, Berk A, Hantel S et al (2013) Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes. Diabetes Care 36:4015–4021CrossRefPubMedPubMedCentralGoogle Scholar
- 82.Barnett AH, Mithal A, Manassie J et al (2014) Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2:369–384CrossRefPubMedGoogle Scholar
- 83.Rosenstock J, Jelaska A, Frappin G et al (2014) Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care 37:1815–1823CrossRefPubMedGoogle Scholar
- 86.Kovacs CS, Seshiah V, Swallow R et al (2014) Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16:147–158CrossRefPubMedGoogle Scholar
- 91.Amin NB, Wang X, Mitchell JR, Lee DS, Nucci G, Rusnak JM (2015) Blood pressure-lowering effect of the sodium glucose co-transporter-2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension. Diabetes Obes Metab 17:805–808CrossRefPubMedGoogle Scholar
- 95.Kashiwagi A, Takahashi H, Ishikawa H et al (2015) A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 diabetes with renal impairment (LANTERN) study. Diabetes Obes Metab 17:152–160CrossRefPubMedPubMedCentralGoogle Scholar
- 96.Kashiwagi A, Kazuta K, Yoshida S, Nagase I (2014) Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 5:382–391CrossRefPubMedGoogle Scholar